Published • loading... • Updated
Novo Nordisk A/S (NYSE: NVO) Holds Zacks Rank #3 As Earnings Estimates Slide And Valuation Looks Attractive
Summary by foreignpolicyjournal.com
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
Novo Nordisk A/S (NYSE: NVO) Holds Zacks Rank #3 As Earnings Estimates Slide And Valuation Looks Attractive
Novo Nordisk A/S (NYSE: NVO) has become one of the most closely watched stocks among visitors to Zacks.com, drawing significant investor attention amid a turbulent recent stretch. Shares of the Danish drugmaker have returned -10.2% over the past month, a sharp contrast to the Zacks S&P 500 composite’s +1.5% gain over the same period. The […]
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
